At Mycovia, we are passionate about developing novel drugs in areas of unmet medical need, with an initial focus in women’s health.

women-jogging.jpg

VT-1161

Our lead product candidate, VT-1161, is being developed as a treatment for recurrent vulvovaginal candidiasis (RVVC), a debilitating chronic condition that affects millions of women worldwide. More commonly known as a chronic yeast infection, RVVC can severely impact a woman’s physical and emotional well being, and results in billions of dollars in lost productivity.

With no FDA-approved treatments for RVVC in the U.S., there are limited treatment options available for women who experience three or more yeast infections a year. Mycovia currently has three Phase 3 clinical studies being conducted to evaluate VT-1161 for the treatment of RVVC and is on path to be the first FDA-approved treatment for this debilitating disease.

While women’s health remains the company’s primary focus, Mycovia recognizes that there is tremendous potential for oral fungal inhibitors to treat a range of multi-drug resistant fungal pathogens.

VT-1161 has also been studied for the treatment of onychomycosis, a fungal infection of the nail, which affects approximately 35 million people in the United States and millions more around the globe. Onychomycosis can be a significant medical issue particularly for people with diabetes or those who have compromised immune systems or poor circulation of the lower extremities. VT-1161 has completed a Phase 2b trial in onychomycosis and met its primary endpoint of complete cure rates at 48 weeks. 

VT-1598

VT-1598 is in Phase 1 development, having shown in vitro and in vivo activity against a range of resistant fungal pathogens that include:

  • Cryptococcus neoformans, which is responsible for cryptococcal meningitis, a serious infection of the brain and spinal column that can occur in people living with HIV

  • Coccidioides, which is responsible for coccidioidomycosis (also known as Valley Fever), a fungal infection on the rise in the Southwestern United States

  • Candida auris, an emerging multi-drug resistant fungal pathogen that presents a serious global health threat

Mycovia Pharmaceuticals was founded in 2018, following the acquisition of Viamet Pharmaceuticals by NovaQuest Capital Management. 


LEADERSHIP

PATRICK JORDAN, MA, MBA
Chief Executive Officer

TIFFANY AHLERS
Senior Vice President, Commercialization

STEPHEN BRAND, PhD
Senior Vice President, Clinical Development

THORSTEN DEGENHARDT, PhD
Senior Vice President, Global Operations

RACHEL GEE
Vice President, Project Management and Regulatory Affairs

KRISTEN OBERG, JD
Vice President, Operations

CAROLINE CARR, CPA
Vice President, Finance